SEHK:9926Biotechs
What Does Akeso (SEHK:9926) China Lung Cancer Approval Mean For Investors?
Akeso (SEHK:9926) received regulatory approval in China for ivonescimab plus chemotherapy as a first-line treatment for advanced squamous non small cell lung cancer.
The decision establishes ivonescimab combination therapy as a new standard of care for this patient group in China.
The approval follows Phase III data that were presented at ASCO and published in The Lancet, which underscores international clinical recognition.
For investors tracking how new oncology drugs and clinical data...